Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | P2B001: a slow-release drug for Parkinson’s disease

Cheryl Fitzer-Attas, PhD, ClinMed LLC, describes P2B001 – a potential therapy for Parkinson’s Disease (PD). P2B001 consists of low-dose, extended-release formulations of two known PD drugs – pramipexole and rasagiline. Rasagiline is an irreversible inhibitor of MAO-B, but recent research has shown additional mechanisms of action of rasagiline and its metabolites. Experts believe that exposure to both rasagiline and pramipexole throughout the day leads to additional clinical benefits for PD patients. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Fitzer-Attas disclosures are that my company, ClinMed LLC, provides Clinical and Medical Affairs services to Pharma Two B.